TRCT
LXEO icon

Tower Research Capital (TRC)’s Lexeo Therapeutics LXEO Stock Holding History

Tower Research Capital (TRC)’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$54.4K Buy
9,485
+8,659
+1,048% +$61.4K ﹤0.01% 2670
2025
Q4 		$8.2K Sell
826
-2,911
-78% -$26.6K ﹤0.01% 3963
2025
Q3 		$24.8K Sell
3,737
-1,357
-27% -$6.56K ﹤0.01% 3106
2025
Q2 		$20.5K Sell
5,094
-771
-13% -$2.54K ﹤0.01% 3668
2025
Q1 		$20.4K Buy
5,865
+4,210
+254% +$18.6K ﹤0.01% 2944
2024
Q4 		$10.9K Buy
1,655
+238
+17% +$1.88K ﹤0.01% 3768
2024
Q3 		$12.8K Sell
1,417
-158
-10% -$1.88K ﹤0.01% 3561
2024
Q2 		$25.3K Buy
1,575
+1,068
+211% +$15.5K ﹤0.01% 3614
2024
Q1 		$7.95K Sell
507
-983
-66% -$15.4K ﹤0.01% 4108
2023
Q4 		$20K Buy
+1,490
New +$18.5K ﹤0.01% 3646

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.71B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return